Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia.
Meekison
W
W
Hutcheon
M
M
Guasparini
R
R
Arnott
M
M
Scheifele
D
D
Grace
M
M
Humphreys
G
G
Barreto
L
L
D001428:Bacterial Vaccines / Q000009:adverse effects*; D001955:British Columbia; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000009:adverse effects*; D005260:Female; D006192:Haemophilus Infections / Q000517:prevention & control*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D011358:Product Surveillance, Postmarketing
D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate